GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (NAS:SCYX) » Definitions » Piotroski F-Score
中文

SCYNEXIS (SCYNEXIS) Piotroski F-Score : 7 (As of Apr. 25, 2024)


View and export this data going back to 2014. Start your Free Trial

What is SCYNEXIS Piotroski F-Score?

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

SCYNEXIS has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for SCYNEXIS's Piotroski F-Score or its related term are showing as below:

SCYX' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 7
Current: 7

During the past 12 years, the highest Piotroski F-Score of SCYNEXIS was 7. The lowest was 1. And the median was 3.


SCYNEXIS Piotroski F-Score Historical Data

The historical data trend for SCYNEXIS's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Piotroski F-Score Chart

SCYNEXIS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 2.00 3.00 - 7.00

SCYNEXIS Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 4.00 7.00 7.00 7.00

Competitive Comparison of SCYNEXIS's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SCYNEXIS's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -33.876 + 122.26 + -1.757 + -19.586 = $67.0 Mil.
Cash Flow from Operations was -18.923 + 74.398 + 12.419 + -7.735 = $60.2 Mil.
Revenue was 1.13 + 131.454 + 1.761 + 5.797 = $140.1 Mil.
Gross Profit was 0.993 + 131.028 + 1.382 + -8.887 = $124.5 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(87.81 + 70.296 + 154.856 + 148.546 + 128.412) / 5 = $117.984 Mil.
Total Assets at the begining of this year (Dec22) was $87.8 Mil.
Long-Term Debt & Capital Lease Obligation was $14.7 Mil.
Total Current Assets was $102.1 Mil.
Total Current Liabilities was $16.3 Mil.
Net Income was -5.451 + -13.345 + -29.584 + -14.429 = $-62.8 Mil.

Revenue was 0.687 + 1.323 + 1.557 + 1.524 = $5.1 Mil.
Gross Profit was 0.588 + 1.179 + 1.368 + 1.328 = $4.5 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(119.837 + 111.562 + 135.612 + 112.293 + 87.81) / 5 = $113.4228 Mil.
Total Assets at the begining of last year (Dec21) was $119.8 Mil.
Long-Term Debt & Capital Lease Obligation was $48.3 Mil.
Total Current Assets was $79.1 Mil.
Total Current Liabilities was $17.6 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

SCYNEXIS's current Net Income (TTM) was 67.0. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

SCYNEXIS's current Cash Flow from Operations (TTM) was 60.2. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=67.041/87.81
=0.76347796

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-62.809/119.837
=-0.52412026

SCYNEXIS's return on assets of this year was 0.76347796. SCYNEXIS's return on assets of last year was -0.52412026. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

SCYNEXIS's current Net Income (TTM) was 67.0. SCYNEXIS's current Cash Flow from Operations (TTM) was 60.2. ==> 60.2 <= 67.0 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=14.74/117.984
=0.12493219

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=48.315/113.4228
=0.42597256

SCYNEXIS's gearing of this year was 0.12493219. SCYNEXIS's gearing of last year was 0.42597256. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=102.116/16.303
=6.26363246

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=79.061/17.618
=4.48751277

SCYNEXIS's current ratio of this year was 6.26363246. SCYNEXIS's current ratio of last year was 4.48751277. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

SCYNEXIS's number of shares in issue this year was 47.922. SCYNEXIS's number of shares in issue last year was 47.556. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=124.516/140.142
=0.88849881

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=4.463/5.091
=0.87664506

SCYNEXIS's gross margin of this year was 0.88849881. SCYNEXIS's gross margin of last year was 0.87664506. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=140.142/87.81
=1.59596857

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=5.091/119.837
=0.04248271

SCYNEXIS's asset turnover of this year was 1.59596857. SCYNEXIS's asset turnover of last year was 0.04248271. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+1+1+0+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

SCYNEXIS has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

SCYNEXIS  (NAS:SCYX) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


SCYNEXIS Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


SCYNEXIS (SCYNEXIS) Business Description

Traded in Other Exchanges
Address
1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.
Executives
David C Hastings director C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Brian Philippe Tinmouth director 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Guy Macdonald director C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Ann Hanham director ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Armando Anido director 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Ivor Macleod officer: Chief Financial Officer 3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634
Scott Sukenick officer: General Counsel 101 HUDSON STREET, SUITE 3610, JERSEY CITY NJ 07302
Marco Taglietti director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Lawrence R Hoffman officer: Interim CFO C/O COVALENT GROUP, INC., 1275 DRUMMERS LANE, SUITE 100, WAYNE PA 19087
Christine Coyne officer: Chief Commercial Officer 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Eric Francois officer: Chief Financial Officer C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713
Gonzalez David Angulo officer: Chief Medical Officer C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713